MCID: INF009
MIFTS: 29

Inflammatory Spondylopathy

Categories: Bone diseases

Aliases & Classifications for Inflammatory Spondylopathy

MalaCards integrated aliases for Inflammatory Spondylopathy:

Name: Inflammatory Spondylopathy 12
Inflammatory Spondylopathies in Disease Classified Elsewhere 12
Inflammatory Spondylopathy in Disease Classified Elsewhere 12
Inflammatory Spondylopathies in Disease Ec 12
Spondylitis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:12105
ICD9CM 35 720.81
SNOMED-CT 68 6963001
ICD10 33 M46.8 M46.9
UMLS 72 C0021396 C0038012

Summaries for Inflammatory Spondylopathy

MalaCards based summary : Inflammatory Spondylopathy, also known as inflammatory spondylopathies in disease classified elsewhere, is related to discitis and spondylitis, and has symptoms including sciatica The drugs Sulfasalazine and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes.

Related Diseases for Inflammatory Spondylopathy

Diseases related to Inflammatory Spondylopathy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 discitis 10.4
2 spondylitis 10.4

Symptoms & Phenotypes for Inflammatory Spondylopathy

UMLS symptoms related to Inflammatory Spondylopathy:


sciatica

Drugs & Therapeutics for Inflammatory Spondylopathy

Drugs for Inflammatory Spondylopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Aceclofenac Approved, Investigational Phase 4 89796-99-6
4
Pamidronate Approved Phase 4 40391-99-9 4674
5
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
6
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
7
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
8
carbamide peroxide Approved Phase 4 124-43-6
9
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
10
Tofacitinib Approved, Investigational Phase 4 477600-75-2
11
Etanercept Approved, Investigational Phase 4 185243-69-0
12
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Loxoprofen Investigational Phase 4 68767-14-6, 80382-23-6 3965
16 Anti-Infective Agents Phase 4
17 Natriuretic Peptide, Brain Phase 4
18 Natriuretic Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Antimalarials Phase 4
21 Antiprotozoal Agents Phase 4
22 Tripterygium Phase 4
23 Mitogens Phase 4
24 Endothelial Growth Factors Phase 4
25 Cholestyramine Resin Phase 4
26 Lipid Regulating Agents Phase 4
27 Hypolipidemic Agents Phase 4
28 Anticholesteremic Agents Phase 4
29 Tocolytic Agents Phase 4
30 Vaccines Phase 4
31 Cyclooxygenase 2 Inhibitors Phase 4
32 Protein Kinase Inhibitors Phase 4
33 Antibodies Phase 4
34 Antibodies, Monoclonal Phase 4
35 Immunoglobulins Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Analgesics Phase 4
39 Peripheral Nervous System Agents Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Antipyretics Phase 4
42 Narcotics Phase 4
43 Central Nervous System Depressants Phase 4
44 Analgesics, Opioid Phase 4
45
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
46
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
47
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
49
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
50
Certolizumab pegol Approved Phase 3 428863-50-7

Interventional clinical trials:

(show top 50) (show all 400)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
3 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
4 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
7 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
8 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
9 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
10 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
11 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
12 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
13 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
14 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
15 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
16 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
17 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
18 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
19 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
20 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
21 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
22 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
23 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
24 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
25 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
26 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
27 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
28 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
29 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
30 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
31 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
32 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
33 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
34 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
35 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
36 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
37 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
38 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Recruiting NCT02492217 Phase 4 Adalimumab
39 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
40 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
41 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
42 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Recruiting NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
43 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
44 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
45 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Active, not recruiting NCT02509026 Phase 4
46 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
47 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Active, not recruiting NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
48 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Active, not recruiting NCT02477150 Phase 4
49 Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Not yet recruiting NCT04062695 Phase 4 Tofacitinib 5 MG Oral Tablet [Xeljanz];Placebo oral tablet
50 Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab Not yet recruiting NCT03623867 Phase 4 Secukinumab;Placebo

Search NIH Clinical Center for Inflammatory Spondylopathy

Genetic Tests for Inflammatory Spondylopathy

Anatomical Context for Inflammatory Spondylopathy

MalaCards organs/tissues related to Inflammatory Spondylopathy:

41
Bone, T Cells, Testes, Spinal Cord, Lung, Endothelial, Heart

Publications for Inflammatory Spondylopathy

Articles related to Inflammatory Spondylopathy:

(show top 50) (show all 15886)
# Title Authors PMID Year
1
Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada. 38
31325731 2019
2
Association of Inflammatory Bowel Disease with Arthritis: Evidence from In Silico Gene Expression Patterns and Network Topological Analysis. 38
29147967 2019
3
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. 38
30692587 2019
4
microRNA-96 promotes osteoblast differentiation and bone formation in ankylosing spondylitis mice through activating the Wnt signaling pathway by binding to SOST. 38
31111563 2019
5
Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey. 38
31111433 2019
6
Erratum: Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with ankylosing spondylitis: A 4-week randomized, open-label study. 38
31423308 2019
7
What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. 38
31122911 2019
8
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. 38
31254223 2019
9
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. 38
31278139 2019
10
Thoracic Manifestations of Ankylosing Spondylitis, Inflammatory Bowel Disease, and Relapsing Polychondritis. 38
31376894 2019
11
Sleep disturbances in ankylosing spondylitis: a systematic review and meta-analysis. 38
31012756 2019
12
Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis. 38
31147969 2019
13
Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study. 38
31342080 2019
14
Clustering of immune-mediated diseases in sarcoidosis. 38
31365389 2019
15
Elevated circulating IL-17 level is associated with inflammatory arthritis and disease activity: A meta-analysis. 38
31271739 2019
16
Differences between females and males in axial spondyloarthritis: data from a real-life cross-sectional cohort. 38
31418321 2019
17
Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. 38
31267570 2019
18
Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. 38
30763469 2019
19
Psoriatic Arthritis Disease Activity During and After Pregnancy: A Prospective Multicenter Study. 38
30192071 2019
20
Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. 38
31396837 2019
21
[Identification of patients with axial spondylarthritis in primary care (AWARE study)]. 38
31375960 2019
22
Impact of Online Prescription Management Systems on Biologic Treatment Initiation. 38
31168763 2019
23
IL-27 in patients with Chikungunya fever: A possible chronicity biomarker? 38
31075222 2019
24
[Change of esophageal length measured on computed tomography after corrective osteotomy for cervicothoracic kyphosis in patients with ankylosing spondylitis and its clinical significance]. 38
31434402 2019
25
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. 38
31436026 2019
26
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. 38
31436036 2019
27
Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. 38
31172372 2019
28
Red cell distribution width, platelet-to-lymphocyte ratio, and mean platelet volume in ankylosing spondylitis and their correlations with inflammation: A meta-analysis. 38
31313609 2019
29
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. 38
31398658 2019
30
Association study of copy number variants in CCL3L1, FCGR3A and FCGR3B genes with risk of ankylosing spondylitis in a West Algerian population. 38
31433132 2019
31
Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. 38
31128893 2019
32
Correction to: It is time for an organised, scientific approach to the application of patient-reported outcome measures in clinical studies and trials. 38
31240419 2019
33
Evaluating and managing low back pain in primary care. 38
31335502 2019
34
Low bone mineral density of vertebral lateral projections can predict spinal radiographic damage in patients with ankylosing spondylitis. 38
31402392 2019
35
Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis. 38
31219006 2019
36
Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore. 38
31090201 2019
37
Aberrant expression of miR‑130a‑3p in ankylosing spondylitis and its role in regulating T‑cell survival. 38
31432140 2019
38
The effects of total hip arthroplasty in treating hip bony fusion in young and middle-aged patients with ankylosing spondylitis. 38
31395063 2019
39
Transient severe conduction disturbances associated with ankylosing spondylitis. 38
31410244 2019
40
Gait as predictor of physical function in axial spondyloarthritis: the prospective longitudinal FOLOMI (Function, Locomotion, Measurement, Inflammation) study protocol. 38
31392500 2019
41
Does vitamin D deficiency contribute to higher disease activity in patients with spondyloarthritis? 38
31226357 2019
42
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. 38
31431486 2019
43
Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study. 38
31172410 2019
44
Coccydynia in a Patient With Ankylosing Spondylitis: Enthesitis or Structural Disorder? 38
31318760 2019
45
Fecal microbiota in patients with ankylosing spondylitis: Correlation with dietary factors and disease activity. 38
31377126 2019
46
A 12-week Baduanjin Qigong exercise improves symptoms of ankylosing spondylitis: A randomized controlled trial. 38
31383427 2019
47
Comparison of Secondary IgA Nephropathy in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis. 38
31370733 2019
48
Reliability and Validity of Patient-Reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis. 38
31371654 2019
49
Diffuse Idiopathic Skeletal Hyperostosis and Ankylosing Spondylitis: Comment on the Article by Latourte et al. 38
30192072 2019
50
Ankylosing spondylitis is associated with aberrant DNA methylation of IFN regulatory factor 8 gene promoter region. 38
30900036 2019

Variations for Inflammatory Spondylopathy

Expression for Inflammatory Spondylopathy

Search GEO for disease gene expression data for Inflammatory Spondylopathy.

Pathways for Inflammatory Spondylopathy

GO Terms for Inflammatory Spondylopathy

Sources for Inflammatory Spondylopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....